Just finished reading through the report and although nothing new, it really does show the signs of a company that is set to deliver some fantastic profits in the years ahead. PromarkerD now in its initial commercialization phase presents good opportunity for investors to top up or new investors to get in before the revenue starts showing up on the P&L. We all know the potential of the revenue with PromarkerD which will soon be the gold standard in CKD testing.
Expenses are reasonable, steady growth from analytics division, new applications for PromarkerD being investigated, healthy cash balance, more cash incoming from R&D grants - passionate CEO/Founder still running the company - what more could we ask for?
Despite the SP, I am happy with the direction Richard is taking the company and I strongly believe patience will be rewarded with this stock.
Just my 2cents guys
PIQ Price at posting:
24.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)